Gefapixant

Drug Profile

Gefapixant

Alternative Names: AF-219; MK-7264; R1646; RG-1646; RO 4926219

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Developer Merck & Co; Roche
  • Class Analgesics; Small molecules
  • Mechanism of Action Purinergic P2X3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Asthma; Cough; Interstitial cystitis; Musculoskeletal pain
  • Discontinued Overactive bladder; Pain

Most Recent Events

  • 09 Nov 2017 Updated efficacy data from a phase IIb trial in Cough presented at the 27th Annual Congress of the European Respiratory Society (ERS-2017)
  • 13 Sep 2017 Merck Sharp & Dohme completes a phase I pharmacokinetic trial (In adults, In the elderly, In volunteers) in USA (PO) (NCT03108924)
  • 09 Sep 2017 Efficacy and adverse events data from a phase II trial in Cough presented at the 27th Annual Congress of the European Respiratory Society (ERS-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top